Sunil Healthcare Ltd

SUNLOCPharmaceuticals
69.61+0.00 (+0.00%)
As on 08 Feb 2026, 11:53 amMarket Closed

Fundamental Score

...

Sunil Healthcare Ltd Share Price Live NSE/BSE

No data
High
0.00
Low
0.00
Volume
0
Change
+0.00%

Profitability Metrics

Poor

Return on Equity

-1.95%
Poor

Return on Capital Employed

3.96%
Average

Operating Profit Margin (5Y)

10.84%
Poor

Dividend Yield

0.00%

Valuation Metrics

Poor

Price to Earnings

42.96x

Market Capitalization

74.32 (Cr)

Industry P/E

31.77x

Growth Metrics

Excellent

YoY Quarterly Profit Growth

281.82%
Average

YoY Quarterly Sales Growth

16.09%
Poor

Sales Growth (5Y)

3.56%
Good

EPS Growth (5Y)

11.44%
Good

Profit Growth (5Y)

11.44%

Financial Health

Poor

Debt to Equity

0.88x
Poor

Interest Coverage

1.36x
Average

Free Cash Flow (5Y)

4.70 (Cr)

Ownership Structure

Good

Promoter Holding

73.53%
Poor

FII Holding

0.00%
Poor

DII Holding

0.10%
Excellent

Pledged Percentage

0.00%
Market-cap Classification
Small-cap
Higher growth potential with higher volatility.
73.53%
Promoter Holding
74.32 (Cr)
Market Cap

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Market Data Analysis & Educational Insights

Educational evaluation of SUNLOC across key market metrics for learning purposes.

Positive Indicators

4 factors identified

Robust Profit Growth (281.82%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.

Strong Revenue Growth (16.09%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.

Balanced Promoter Holding (73.53%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral, reducing forced-selling risk.

Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.

Risk Factors

10 factors identified

Below-Average Return on Equity (-1.95%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (3.96%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.

Premium Valuation Risk (P/E: 42.96x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.

Limited Growth History (3.56% CAGR)

Observation: Below-average 5-year sales growth trajectory.

Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities. Assess future growth catalysts.

Weak Interest Coverage (1.36x)

Observation: Limited ability to service debt obligations from earnings.

Analysis: Low interest coverage raises concerns about financial stability. Monitor cash flow and debt reduction plans.

Limited Institutional Interest (FII+DII: 0.10%)

Observation: Low institutional participation may affect liquidity and visibility.

Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.

Very Low ROE

Observation: Poor capital utilization and shareholder returns.

Analysis: ROE below 5% suggests significant inefficiencies in capital deployment.

High P/E Ratio

Observation: Stock may be overvalued relative to earnings.

Analysis: P/E above 30 requires strong growth execution to justify current valuations.

Small Market Cap

Observation: Higher investment risk due to limited size.

Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.

Financial Statements

Comprehensive financial data for Sunil Healthcare Ltd

About SUNLOC

Business Overview

Sunil Healthcare Limited engages in the manufacture and sale of empty hard gelatin, hydroxypropyl methylcellulose (HPMC), and pullulan capsules shells in India and internationally. Its products include EHG, BSE/TSE free, pearl, liquid fill, preservative free, stick free, flavored, SLS free, natural color, non-AZO, gelatin, HPMC/vegetable, and pullulan capsules. The company also provides ayurvedic products, such as haldi, ginger, vasaka, trifala, guduchi, salaki, punarvana, shatavari, hadjod, hingwastak, mulethi, arjuna, ashwagandha, and guggul extracts. The company offers its products under the SUNLOC brand name. Sunil Healthcare Limited was incorporated in 1973 and is based in New Delhi, India.

Company Details

Symbol:SUNLOC
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Anil Kumar Khaitan
Chairman, CEO & MD
Mr. Pawan Rathi
Chief Financial Officer
Mr. Ishan Khaitan
President of Operation & Marketing

SUNLOC Stock Details & Analysis

Key Financial Metrics

Return on Equity (ROE)-1.95%
Return on Capital Employed3.96%
Operating Profit Margin (5Y)10.84%
Debt to Equity Ratio0.88
Interest Coverage Ratio1.36

Growth & Valuation

Sales Growth (5Y)3.56%
Profit Growth (5Y)11.44%
EPS Growth (5Y)11.44%
YoY Quarterly Profit Growth281.82%
YoY Quarterly Sales Growth16.09%

Frequently Asked Questions

What is the current price of Sunil Healthcare Ltd (SUNLOC)?

As of 08 Feb 2026, 11:53 am IST, Sunil Healthcare Ltd (SUNLOC) is currently trading at ₹69.61. The stock has a market capitalization of ₹74.32 (Cr).

Is SUNLOC share price Overvalued or Undervalued?

SUNLOC is currently trading at a P/E ratio of 42.96x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.

What factors affect the Sunil Healthcare Ltd share price?

Key factors influencing SUNLOC's price include its quarterly earnings growth (Sales Growth: 16.09%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).

Is Sunil Healthcare Ltd a good stock for long-term investment?

Sunil Healthcare Ltd shows a 5-year Profit Growth of 11.44% and an ROE of -1.95%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.88 before investing.

How does Sunil Healthcare Ltd compare with its industry peers?

Sunil Healthcare Ltd competes with major peers in the Pharmaceuticals. Investors should compare SUNLOC's P/E of 42.96x and ROE of -1.95% against the industry averages to determine its competitive standing.

What is the P/E ratio of SUNLOC and what does it mean?

SUNLOC has a P/E ratio of 42.96x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹43 for every ₹1 of annual earnings.

How is SUNLOC performing according to Bull Run's analysis?

SUNLOC has a Bull Run fundamental score of 37.8/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.

What sector and industry does SUNLOC belong to?

SUNLOC operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Sunil Healthcare Ltd.

What is Return on Equity (ROE) and why is it important for SUNLOC?

SUNLOC has an ROE of -1.95%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Sunil Healthcare Ltd generates profits from shareholders' equity.

How is SUNLOC's debt-to-equity ratio and what does it indicate?

SUNLOC has a debt-to-equity ratio of 0.88, which indicates moderate leverage that should be monitored. A ratio below 1.0 generally indicates conservative financing.

What is SUNLOC's dividend yield and is it a good dividend stock?

SUNLOC offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.

How has SUNLOC grown over the past 5 years?

SUNLOC has achieved 5-year growth rates of: Sales Growth 3.56%, Profit Growth 11.44%, and EPS Growth 11.44%.

What is the promoter holding in SUNLOC and why does it matter?

Promoters hold 73.53% of SUNLOC shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.

What is SUNLOC's market capitalization category?

SUNLOC has a market capitalization of ₹74 crores, placing it in the Small-cap category.

How volatile is SUNLOC stock?

SUNLOC has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.

What is the 52-week high and low for SUNLOC?

SUNLOC has a 52-week high of ₹N/A and low of ₹N/A.

What is SUNLOC's operating profit margin trend?

SUNLOC has a 5-year average Operating Profit Margin (OPM) of 10.84%, indicating the company's operational efficiency.

How is SUNLOC's quarterly performance?

Recent quarterly performance shows YoY Sales Growth of 16.09% and YoY Profit Growth of 281.82%.

What is the institutional holding pattern in SUNLOC?

SUNLOC has FII holding of 0.00% and DII holding of 0.10%. Significant institutional holding often suggests professional confidence in the stock.